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Initial evidence suggested that people with Complex R gional Pain Syndrome (CRPS) have 








related to pain and other clinical symptoms. Three previous unblinded, uncontrolled studies 
showed pain relief following treatment with prism adaptation, an intervention that has been 
used to counter lateralised attention bias in brain-lesioned patients. To provide a robust test of 
its effectiveness for CRPS, we conducted a double-blind randomized controlled trial of prism 
adaptation for unilateral upper-limb CRPS-I. Forty-nine eligible adults with CRPS were 
randomized to undergo two-weeks of twice-daily home-based prism adaptation treatment (n 
= 23) or sham treatment (n = 26). Outcomes were assssed in person four weeks prior to and 
immediately before treatment, and immediately after and four weeks post-treatment. Long-
term postal follow-ups were conducted three and six months after treatment. We examined 
the effects of prism adaptation versus sham treatment on current pain intensity and CRPS 
symptom severity score (primary outcomes); as well as sensory, motor, and autonomic 
functions, self-reported psychological functioning, and experimentally tested 
neuropsychological functions (secondary outcomes). We found no evidence that primary or 
secondary outcomes differed between the prism adapttion and sham treatment groups when 
tested at either time point following treatment. Overall, CRPS severity significantly 
decreased over time for both groups, but we found no benefits of prism adaptation beyond 
sham treatment. Our findings do not support the efficacy of prism adaptation treatment for 
relieving upper-limb CRPS-I. This trial was prospectively registered (ISRCTN46828292). 
Keywords: complex regional pain syndrome; Prism adaptation; Randomized controlled trial; 
attention; pain; CRPS symptom severity; body representation; Neuropsychology; Neglect 
 
1. Introduction 
Complex Regional Pain Syndrome (CRPS) is associated with continuous pain in one or more 








to any inciting injury [35]. Individuals with CRPS can also show neuropsychological 
symptoms reminiscent of hemispatial neglect after brain injury [33]. These can present as 
distorted cognitive representations of the CRPS-affected limb(s) [45,50,72,85,94], reduced 
attention to the affected limb(s) and corresponding side of external space [11,21,25,27,76,84], 
poorer mental representation of the affected side of space [99], and spatially-defined motor 
deficits [84]. The extent of these neuropsychological changes has been associated with the 
severity of clinical signs of CRPS [25,46,50,75,76,84,85,105] and could pertain to its central 
mechanisms [86]. 
Prism adaptation (PA) is a sensorimotor training technique used to reduce lateralised biases 
in attention, spatial representations, and (ocular)motor performance in hemispatial neglect 
after brain injury [55,69,90]. Considering similar neuropsychological deficits in CRPS, three 
previous studies tested the efficacy of PA in a totl f 13 patients with this condition. They 
reported significant relief of pain and other CRPS symptoms following eight to 20 PA 
sessions performed with the affected arm when participants adapted towards their affected 
side [9,12,100]. The reduction in pain lasted up to tw  weeks. Thus, PA has the potential to 
durably relieve pain and other symptoms of CRPS. Because PA is quick (5-10 minutes a 
day), inexpensive, and self-administered, it is an appealing intervention compared to more 
intensive neurocognitive treatments like graded motor imagery [73]. However, the strength of 
available evidence for PA is limited, because it was only tested in small samples, without any 
control treatments or blinding. 
The mechanisms through which PA could relieve pain are unclear. One possibility is that it 
increases attention to the CRPS-affected side relativ  to the unaffected side. Indeed, when 
one patient underwent adaptation in the opposite direction such that the theoretical attention 
bias away from the affected side would be exacerbatd, their pain increased [100]. More 








been related to greater pain intensity and worse long-term pain outcomes [25,84,85,105]. A 
potential second mechanism is that PA restores normal sensorimotor integration, the 
disruption of which is thought to contribute to pathological pain, including CRPS 
[8,38,63,100]. This is consistent with findings that individuals without spatial biases can also 
benefit from PA [12].  
We conducted a double-blind, randomized, sham-controlled trial of PA for upper-limb 
CRPS-I. We hypothesised that two weeks of twice-daily PA treatment would reduce the 
primary outcomes of pain intensity and CRPS symptom severity more than sham treatment of 
the same intensity. We also predicted greater reductions in the secondary outcomes of 
neuropsychological symptoms (i.e. biases in spatial cognition, motor control, and body 
representation), clinical signs of CRPS, and self-repo ted CRPS-related and psychological 
disturbances following PA compared to sham treatmen. The outcomes were assessed at six 
time points: to establish a one-month pre-treatment baseline, and to examine any immediate 
effects of PA and their retention at one, three, and six months post-treatment. 
 
2. Methods 
2.1. Study design and participants 
The study was a two-arm parallel group RCT. It was prospectively registered 
(ISRCTN46828292 [42]) and the full details of the study are reported in the study protocol 
and analysis plan [34]. Any protocol deviations are sp cified in the relevant sections of the 
article. Anonymised participant-level data generated during the current trial 
(https://osf.io/ba6fq/), digital study materials (training protocol and video, PsychoPy 
experiment files and stimuli; https://osf.io/7fk2v/), and analysis scripts (https://osf.io/w67rx/) 








the UK National Health Service (NHS) Oxfordshire Research Ethics Committee A and 
Health Research Authority (reference 12/SC/0557).  
We aimed to address the following research questions: 
(1) Is two weeks of twice-daily PA treatment more effective in reducing pain and CRPS 
symptom severity than sham treatment? 
(2) Are there any improvements in other clinical signs of CRPS, psychological functioning, 
and neuropsychological symptoms following PA treatment? 
(3) How long are any benefits sustained for after the cessation of PA treatment? 
(4) Are there factors that can predict the CRPS progression over time and/or the response to 
PA treatment? 
(5) Are the neuropsychological abnormalities in CRPS (as compared to pain-free controls) 
related to clinical signs of CRPS? 
Participants with CRPS were primarily recruited for the current RCT of PA treatment 
(questions 1-4), but we also collected measures of spatial cognition, motor control, and body 
representation at baseline (RS1) for comparison with pain-free controls and correlational 
analysis with clinical signs of CRPS (question 5; data reported elsewhere [32]).   
Recruitment was conducted via post through the Nation l CRPS-UK Registry, internal 
registries of the Royal United Hospitals and Walton Centre NHS Foundation Trusts, and 
clinicians’ referrals through the Oxford University Hospitals NHS Foundation Trust and 
other NHS pain clinics in the UK. Word of mouth, print and online advertisements, as well as 
social media were further used to disseminate information about the study. Participants were 
recruited between March 2017 and December 2018, and the final long-term follow-up took 








Following provisional assessment of eligibility through a phone interview, recruited 
participants took part in four research sessions (RS) at the University of Bath (n = 33), 
University of Liverpool (n = 9), or in the participant’s home (for participants who were 
unable to travel; n = 7). Participants gave written informed consent at the beginning of RS1, 
prior to any study-related procedures. The research sessions involved in-person assessment of 
eligibility criteria and of the primary and secondary outcomes, including self-report 
questionnaires, clinical assessments, and tests of neuropsychological functions. Each RS 
lasted from two to four hours, including breaks between the assessments. The data collection 
schedule is presented in Figure 1. The baseline was me sured over two research sessions 
(RS1 and RS2) separated by four weeks. Immediately fter RS2, participants commenced a 
two-week home-based treatment period. Treatment outcomes were measured over two 
research sessions, one immediately (RS3) and one four weeks (RS4) after completing the 
treatment. Two long-term follow-ups were conducted via post – one at 12 weeks (LTFU1) 
and one at 24 weeks (LTFU2) after completing the treatment. The flow of participants 
through each stage of the study is displayed in a CONSORT diagram (Figure 2). 
[Figure 1] 
[Figure 2] 
Participant inclusion criteria were: being aged 18-80 years; having a diagnosis of CRPS-I 
primarily affecting one upper limb based on the Budapest research criteria [35]; having a 
CRPS diagnosis for ≥3 months at the time of RS1; and having a current pain intensity ≥2 on a 
0-10 Numeric Rating Scale. Exclusion criteria were: lacking sufficient English language 
ability to provide informed consent; being classified as legally blind; reporting a history of 
neurological disorder (e.g. stroke, neurodegenerative disease, or traumatic brain injury); 








reporting confirmed nerve damage (CRPS-II); reporting or showing dystonia or other 
physical impairment that would prevent satisfactory execution of PA/sham treatment; or 
reporting severe psychiatric comorbidity (e.g. schizophrenia [102]) that could be associated 
with perceptual changes. Inclusion and exclusion criteria were assessed in RS1 and RS2. 
2.2. Interventions 
Both groups were instructed to continue any usual tre tments (including medications) but 
were asked not to change their treatment regimens throughout the duration of the trial if 
possible. Current treatments and any changes are reported in Supplemental Table S1 
(available at http://links.lww.com/PAIN/B162). 
2.2.1. Prism adaptation treatment 
Participants randomised to the PA treatment used wel ing goggles fitted with 35-diopter 
Fresnel lenses that induced approximately 19° lateral optical deviation (visual shift) away 
from the CRPS-affected side. In each treatment session, participants were seated 
approximately 50 cm from a wall or other vertical surface (the actual distance was adjusted 
individually to correspond to the participant’s almost fully extended arm, thus it differs from 
the 60 cm distance anticipated in the trial protocol [34]). An A4 sheet was positioned on the 
wall in a landscape orientation at eye-level and in line with their body midline. There were 
two targets (2 cm-diameter red circles) on the pointing sheet, located 12.5 cm to the left and 
12.5 cm to the right of participant’s body midline. While wearing the prism goggles, 
participants used their CRPS-affected arm to perform 50 pointing movements, as fast as 
possible, alternating between the left and right target. 
An example of prism adaptation is illustrated in Figure 3. Prismatic shifts were directed away 
from the CRPS-affected side, thus participants withleft-CRPS would use rightward-shifting 








initially err to the right. However, with repeated movement execution and motor learning, the 
pointing would become increasingly accurate, as the movements would adjust in the opposite 
direction (to the left). This adaptive realignment of sensorimotor reference frames [82,101] 
would produce movement after-effects towards the left (affected) side. That is, once the 
goggles were removed, if participants were to point to the target again, their pointing would 
temporarily err to the left. Conversely, participants with right-CRPS would use leftward-
shifting prismatic goggles to induce adaptive realignment (movement after-effects) towards 
their affected side. Studies from neurologically healthy individuals and stroke patients show 
that these short-term movement after-effects are accompanied by a longer-lasting realignment 
of attention, spatial representations, and lateralised (ocular)motor performance in the same 
direction as the after-effect  [3,14,24,43,47,53–55,6 ,66,69,89,90,95,96,98,104].  
[Figure 3] 
The chosen direction of PA, inducing a visual shift away from the affected side and thereby 
an after-effect towards the affected side, is consistent with previous PA studies in CRPS 
[9,12,100] and the technique’s application in rehabilit tion of hemispatial neglect after brain 
injury [55,90]. To enhance the effects of PA, welding goggles occluded the first half of the 
arm movement and participants were encouraged to point as quickly as possible. Both of 
these measures are thought to reduce any deliberate mis-aiming on behalf of the participants 
and encourage greater adaptive realignment (i.e. “true” sensorimotor adaptation) [19,82,83]. 
Previous studies in hemispatial neglect and CRPS demonstrated that the chosen number of 
movements (50 per session) is sufficient to induce adaptation measured as pointing after-
effects, and changes in spatial cognition [9,90,100]. Note that the immediate movement after-








Immediately after RS2, participants were trained in person in how to carry out the treatment 
by a research psychologist JHB or ADV (neither of whom were involved in any data 
collection) according to a standardised protocol (avail ble in study materials). Once the 
researcher was satisfied that the participant understood the treatment procedure, they 
performed the first treatment during this training session under the guidance of the researcher. 
At the end of the training session participants received a pair of prism goggles in a sealed 
opaque bag, a pointing sheet, written instructions, a d a link to a video tutorial to take home. 
In addition to the treatment that they underwent during training, participants were instructed 
to perform twice-daily self-guided treatment session  at home for two weeks, resulting in 29 
treatment sessions in total. The number of sessions per day and days of treatment were based 
on regimens that have previously been shown to reduce hemispatial neglect following stroke 
[23,24,47,69,95,96]. This regimen was also more intnse than those used in previous studies 
demonstrating CRPS reduction following PA treatment [9,12,100], however we also 
considered that it would not be too much of a burden for participants. They were instructed to 
commence the home-based treatment on the day following RS2, perform one session in the 
morning and on in the evening, and record the startand end time of each session in a 
provided logbook.  
2.2.2. Sham treatment 
Participants randomized to the sham treatment carried out exactly the same procedure as 
described above, except they used welding goggles fitt d with neutral lenses that did not 
induce any lateral visual shift [10,69]. The neutral lenses distorted the acuity and clarity of 
vision to a similar extent as prism lenses (only without any lateral shift), therefore the two 








2.3. Randomisation and blinding 
Participant randomization was performed 1-5 days before RS2 by JHB, who was not involved 
in any data collection. Participants were randomly assigned to either PA or sham treatment 
group with equal allocation ratio, using MINIM [68] software to minimize baseline (RS1) 
group differences in current pain intensity, CRPS severity score, primarily affected arm, pre-
CRPS dominant hand, sex, age, presence of CRPS in other body parts, presence of other non-
CRPS pain, and CRPS duration. The primary outcome measures (current pain intensity and 
CRPS severity score) were given double weighting compared to the other minimisation 
characteristics as we considered matching the two groups for these factors to be a higher 
priority. Note that this allocation procedure was updated in the trial registration [42] after the 
first two participants were enrolled and provided RS1 data, but before they were allocated to 
treatment. The update reflects the use of MINIM software instead of blocked minimization to 
automate the allocation procedure. As per the trial p otocol [34], participants excluded 
between treatment allocation and RS3 (Figure 2) were r moved from the minimization 
procedure so that subsequently recruited participants could be allocated independent of these 
exclusions and according to the current pool of participants remaining in each arm.  
The only researchers who were aware of individual treatment allocations were those who 
randomised the participants and/or trained them in carrying out PA or sham treatments and 
provided them with prism or neutral goggles (JHB and/or ADV). These researchers were not 
involved in the assessments of any outcomes at any poi t in the trial. In RS3, the participants 
returned the goggles in a sealed opaque bag to MH, which she handed unopened to JHB. The 
researcher responsible for enrolment and all data collection (MH) remained blinded to 
participants’ treatment allocation until the last participant completed their RS4. Following 
RS4, there were no further in-person assessments as the long-term follow-up was conducted 








blinded to their treatment allocations throughout the entire duration of the trial. They were 
informed that they might receive real or sham treatment, and that both involved reaching out 
to touch visual targets with their affected arm while wearing goggles that distort vision. 
However, participants were not made aware of the specific nature of the intervention nor the 
differences between the types of goggles used in the two treatment arms. All documentation 
and instructions referred to the treatment arm as “sensorimotor training”. 
2.4. Measures 
2.4.1. Demographics  
In RS1, participants reported on demographic characte istics, including age, sex, and 
handedness prior to CRPS onset. They completed two versions of Edinburgh Handedness 
Inventory [78]: rating their recalled (prior to CRPS onset) and current hand preference. Total 
scores can range from -100 (extreme left-handedness) to 100 (extreme right-handedness). To 
approximate the functional impact of CRPS, we calcul ted an absolute difference between 
current and recalled handedness scores, that is, change in handedness. We also interviewed 
the participants regarding their clinical history, including the date and type of any inciting 
injury, CRPS duration (time since diagnosis), any co-morbidities, and any ongoing treatments 
for CRPS.  
2.4.2. Primary outcomes 
The primary research question was (1) whether two weeks of twice-daily PA treatment is 
more effective in reducing pain and CRPS symptom severity than sham treatment. Change 
between RS2 and RS3 in current pain intensity and CRPS symptom severity score were the 
primary outcomes. In RS1-RS4 and LTFU1-LTFU2, participants rated their current pain 
intensity in the CRPS-affected limb on a Numerical R ting Scale from 0 (no pain) to 10 (pain 








[13], and has been recommended as a core outcome for chronic pain trials [17,31]. CRPS 
severity was assessed in RS1-RS4 according to a standardised protocol [34,37]. Eight self-
reported symptoms and eight signs evaluated upon clinical examination were scored as 0 
(absent) or 1 (present) based on sensory testing, and visual and manual examination. The 
summed CRPS severity score can range from 0 (no CRPS symptoms) to 16 (most severe 
CRPS symptoms). The CRPS severity score has good discrim nation abilities, concurrent 
validity, and adequate sensitivity to change [36,37], and was recommended as the core 
outcome measure for CRPS clinical studies [31]. 
2.4.3. Secondary outcomes 
Our secondary research question was (2) whether there ar  any improvements in other 
clinical signs of CRPS, psychological functioning, and neuropsychological symptoms 
following PA treatment. Detailed description of and rationale for the secondary outcome 
measures is available in a published study protocol [34]. Below we provide the basic details 
of how these outcomes were quantified.  
2.4.3.1. Self-report measures 
Self-reported secondary outcomes measured in RS1-RS4 and LTFU1-LTFU2 included 
questionnaires about pain, body representation, and emotional functioning. These were 
chosen based on recommendations for core outcome measures for chronic pain trials [17] and 
the existing literature on CRPS implicating other relevant measures (e.g. [30]). For pain-
related outcomes, we used the Brief Pain Inventory (0-10 scale for each subscale; higher 
scores indicate greater pain intensity/interference [13]) and Pain Detect Questionnaire (-1-38 
scale; higher scores indicate greater neuropathic component of experienced pain [26]). Body 
representation was measured using the Bath CRPS Body Perception Disturbance Scale (0-57 








Tampa Scale for Kinesiophobia (17-68 scale; higher sco es indicate more severe pain-related 
fear of movement and re-injury [67]) and Profile of Mood States (17-229 scale; higher scores 
indicate greater mood disturbance [64]). In RS1, participants also completed Revised Life 
Orientation Test (0-24 scale; higher scores indicate higher optimism level [93]), and Patient 
Centred Outcomes Questionnaire (each item rated on 0-10 scale; higher scores indicate 
higher usual, desired, expected, and considered succe sful in terms of the treatment outcome 
levels of pain, fatigue, emotional distress, and interference, and higher importance of 
improvement in each of these areas [87]). These two measures were included to assess 
whether two treatment groups were matched on their av age optimism and expectations of 
outcomes, because these factors can affect the succss of novel treatments [4,51,103]. In 
post-treatment RS3-4 and LTFU1-LTFU2, participants ra ed their impression of how much 
their activity limitations, symptoms, emotions, and overall quality of life related to CRPS 
changed due to treatment, using the Patient Global Impression of Change questionnaire (1-7  
scale; 1 indicates no change or worsening of symptos; higher scores indicate greater 
improvement [40]).  
Throughout the first 10 weeks of the trial (RS1-RS4), participants rated their average level 
(over the past 24 hours) of pain intensity, the degre  to which their symptoms interfered with 
their daily life, and range of movement in the affected limb, using daily logbooks (0-10 
Numerical Rating Scales; higher scores indicate greate  pain intensity, symptoms 
interference, and better range of movement), to track the precise time course of any changes 
on these outcomes. 
2.4.3.2. Clinical assessments 
In RS1-RS4 we assessed participants’ CRPS signs and ymptoms to determine whether the 








in-person assessments, photographs and videos of both limbs were double-scored for the 
presence of colour asymmetry, dystrophic changes, and motor abnormalities by a trained 
research assistant who was blind to treatment allocation, affected limb, and time point of 
assessment. Cohen’s kappa statistics for inter-rate agr ement were significantly different 
from zero, indicating fair agreement for colour asymmetry (κ = .21, p = .004) and dystrophic 
changes (κ = .23, p < .001), and borderline slight/fair agreement for motor impairment (κ = 
.20, p < .001). We also objectively quantified sensory, autonomic, and motor functions. 
Sensory tests were performed on the most painful site on the CRPS-affected limb and the 
corresponding site on the unaffected limb (assessed first), unless specified otherwise.  
Secondary outcomes of sensory function of the affected relative to unaffected limb included 
elements of quantitative sensory testing administered according to the standardised protocol 
[34,88]. Specifically, we measured Mechanical Detection Thresholds using von Frey 
filaments. A positive threshold ratio [(affected-unaffected)/affected] indicates increased 
tactile detection threshold (hypoesthesia) on the affected side. We measured Mechanical Pain 
Thresholds using pinprick stimulators. A positive threshold ratio [(unaffected-
affected)/unaffected] indicates decreased pain threshold (hyperalgesia) on the affected side. 
Allodynia was assessed using a cotton ball, a Q-tip, and a brush. An arithmetic mean of 15 
ratings for these sensations from 0 (no sharp, pricking, stinging, or burning sensation) to 100 
(most intense pain sensation imaginable) quantifies th  severity of allodynia on the affected 
limb. We also measured Two-Point Discrimination thresholds on participants’ index 
fingertips according to a staircase procedure using a disk with one and two plastic tips 
separated by 2-15mm distance. A positive threshold ratio [(affected-unaffected)/affected] 
indicates higher tactile discrimination threshold (less precise discrimination ability) on the 








In addition to contributing to the CRPS severity score, the following measures were used as 
secondary outcomes of autonomic and motor function of the affected relative to unaffected 
limb: temperature difference (affected–unaffected; a negative score indicates that the affected 
limb was colder; absolute values were also analysed); o ema (affected–unaffected; higher 
scores indicate greater swelling of the affected limb); grip strength (affected/unaffected; 
scores <1 indicate weaker strength of the affected hand); and delta finger-to-palm distance 
(affected/unaffected; scores <1 indicate lower range of movement of the affected hand).  
2.4.3.3. Tests of neuropsychological functions 
In RS1-RS4, the participants completed six experimental tests of the following 
neuropsychological functions: visuospatial attention in near space (Temporal Order 
Judgement, Landmark, and Greyscales tasks); mental r presentation of space (Mental 
Number Line Bisection task); spatially-defined motor function; and body representation 
(Hand Laterality Recognition task). A comprehensive battery of sensitive tests of distinct 
aspects of spatial cognition, motor control, and boy representation deemed appropriate to 
fully capture any neuropsychological biases, how they would be affected by PA, and how 
they would relate to any changes in pain and other CRPS symptoms. Below we summarise 
how the neuropsychological functions were measured and quantified, whereas detailed 
descriptions of the experimental materials and procedures can be found in the trial protocol 
[34].   
All experimental tasks were programmed and administered using PsychoPy software [79]. 
Those involving presentation of visual stimuli on a computer screen used a 34.5cm x 19.4cm 
touchscreen positioned at 50cm viewing distance. In all tasks (except the Mental Number 
Line Bisection), participants used a chinrest and fixated on a cross aligned with their body 








press the buttons, which were aligned orthogonally to the required response format (i.e. for 
left/right responses, participants pressed colour-cded bottom/top buttons). A short practice 
session was completed before each task. Data for stimuli/responses in the left and right sides 
of space for all tasks were recoded after collection in terms of affected and unaffected space 
relative to each participant’s CRPS-affected side.  
The Temporal Order Judgement task measures covert spatial attention. Participants saw pairs 
of brief, identical light flashes, presented with different temporal offsets (±10-240ms range) 
onto a white table surface, one on each side of space. In one block participants reported 
which of the two lights they perceived first by saying “left” or “right”. In another block they 
reported which light they perceived second. The order of response type (first or second) was 
counterbalanced and results were averaged across these to account for any response bias [22]. 
We calculated the Point of Subjective Simultaneity, which expresses by how many 
milliseconds the light in the affected side of space had to precede (negative score) or follow 
(positive score) the light in the unaffected side of space for both lights to be perceived as 
simultaneous. Information that receives greater attntion is perceived earlier than information 
that receives lesser attention [97]. Thus, a negative Point of Subjective Simultaneity indicates 
lower attention to the affected side of near space relative to the unaffected side.  
The Landmark task [57] measures the visual representatio  of relative horizontal distance in 
near space. Participants saw pairs of landmarks (white circles) presented simultaneously, one 
on each side of space. While the distance between two landmarks was constant across all 
trials, their relative distance from the central fixat on cross varied by 0.1° increments from 
±8.1° to ±6.9° to the left and to the right. Participants indicated via a button press whether the 
left or the right landmark appeared closer to or further from the fixation cross. Results were 
averaged across two separate response blocks to account for any response bias. We calculated 








landmark on the affected side of space had to be further from (negative score) or closer to 
(positive score) the fixation cross in order to perceive the two landmarks to be equidistant. A 
negative Point of Subjective Equality value indicates underestimation of the distance on the 
affected relative to the unaffected side, and thus underrepresentation of the affected side of 
near space.  
The Greyscales task [77] measures overt spatial attention. Participants saw pairs of horizontal 
bars filled with greyscales presented one above the ot r. The two bars were mirror images of 
each other so that one bar was darker on the left sid  and the other bar was darker on the right 
side. Participants pressed a button to indicate which bar appeared to be darker overall. A 
negative value of the calculated index of spatial bi s indicates that a higher proportion of 
overall darkness judgements was made based on the unaffected sides of the stimuli, 
consistent with lower attention to the affected relative to unaffected side.  
The Mental Number Line Bisection task [99] measures m ntal representation of space, based 
on an implicit representation of numbers in a left-to-right linear arrangement [15]. The 
experimenter read aloud pairs of numbers that were s parated by an interval of 9-64 digits. 
They were presented in ascending and descending order (e.g. 54 and 70, or 70 and 54) to 
account for any response bias. Participants were instructed to verbally report the subjective 
midpoint between the given pair of numbers, without making any calculations. A negative 
value of the calculated index of spatial bias is consistent with overestimating the subjective 
midpoint towards larger numbers (i.e. a rightward bias). Expressed relative to each 
participant’s CRPS-affected side, a negative index indicates a bias away from the affected 









The spatially-defined motor function task [59] measure  directional hypokinesia and 
directional bradykinesia, that is slowing of initiation and execution of movements directed 
towards the affected relative to unaffected side. On each trial, participants held down a button 
with their finger until the target appeared either on the left or on the right side of a computer 
screen. Then participants were required to release the button, touch the target on the screen, 
and return their finger to the button as quickly as po sible. Participants completed the task 
from three starting positions (button positioned to the left, right, or aligned with their body 
midline; order counterbalanced), alternating between th ir unaffected and affected hand, 
across six blocks in total. We used average movement initiation times (from the target onset 
to button release) and movement execution times (from the button release to touch on the 
computer screen) for each combination of hand starting position and target location to 
calculate indices of directional hypokinesia and bradykinesia towards the affected side [92], 
separately for each hand used to complete the task. Index A quantifies the speed of 
initiating/executing movements towards the affected side relative to the unaffected side. This 
index was calculated as: [central starting position (affected – unaffected target location) – 
affected starting position (affected – unaffected target location)]. Index A allows to dissociate 
motor and perceptual neglect (i.e. effect of target location), however, it involves movement 
trajectories of different length. Thus, we also derived Index B that directly quantifies the 
speed of initiating/executing movements of the same physical length towards the affected 
side relative to the unaffected side. Index B was calculated as: [central starting position 
(affected target location) – affected starting positi n (affected target location)]. Positive 
values of indices A and B indicate slowing of initiation/execution of movements directed 
towards the affected relative to unaffected side, suggestive of directional 








The Hand Laterality Recognition task [94] measures body representation. Participants saw 
images of hands appearing either to the left or to the right of central fixation. The images 
depicted left or right hands in different postures and rotations from upright (0°, 90°, 180°, or 
270°). Participants were required to indicate as fast and as accurately as possible (via a button 
press) whether each image depicted a left or a right hand. Accuracy rates and average 
reaction times to correctly responded-to trials for each depicted hand were averaged across 
two image locations, because the side of space effects were not the primary interest of this 
trial and will be reported elsewhere. We calculated two indices of hand laterality recognition 
as the differences between the depicted hands: accuracy index (unaffected hand – affected 
hand) and reaction time index (affected hand – unaffected hand). Positive scores indicate less 
accurate and slower recognition of depicted hands corresponding to participant’s affected 
hand, relative to depicted hands corresponding to their unaffected hand. Thus, positive 
accuracy and reaction time indices suggest distorted representation of the CRPS-affected 
limb. 
2.5. Statistical analyses 
2.5.1. Sample size calculation 
The study was powered to evaluate the effects of PA treatment on a change in the primary 
outcome of pain intensity between RS2 and RS3. We estimated [18] that a sample of 21 
participants with CRPS per treatment group would provide 90% power to detect a minimal 
clinically significant reduction of 2 on the primary outcome of pain intensity (0-10 NRS; 
[20]), with a SD of 1.98 (based on our previous research [11]), and a 2-tailed alpha of 0.05. 
Although we aimed to obtain 42 complete data sets for RS1-RS4, one participant in the sham 
treatment group withdrew after we terminated recruitment, thus the total number of 









The analysis plan can be found in the trial protocol [34], thus below we only describe the 
main steps, any details not previously specified, an  ny deviations from the protocol. We 
used IBM SPSS Statistics 25 [41], R 3.5.3 [81], and MATLAB 2018b [58] software to 
process and analyse the data. Data preparation procedures are reported in Supplemental Text 
S1 (available at http://links.lww.com/PAIN/B162). Throughout, we reported bootstrapped 
bias-corrected and accelerated 95% confidence intervals (BCa 95% CIs) around all mean and 
median values. We used bootstrapped χ2 tests, bootstrapped t-tests (or their non-parametric 
alternatives in case of violation of parametric assumptions), and ANOVAs to compare mean 
values between treatment groups and between data collection time points. ANOVA is robust 
to moderate violations of normality and homogeneity of variance [6,7], and we used 
Greenhouse-Geisser corrections if the sphericity assumption was violated. However, where 
severe (i.e. more than borderline significant and in multiple conditions) violations of the 
assumptions of normality, homogeneity of variance, and sphericity were found, we used 
linear mixed models analyses with non-parametric bootstrapping procedures (n = 1000). For 
linear mixed models analyses, a model term made a significant contribution to predicting an 
outcome when the 95% CI around the coefficient estimate (B) did not include zero. For the 
remaining analyses, statistical significance was defined as p < .05. We used one-tailed tests 
for comparisons for which we had directional hypotheses (i.e. RS2 vs. RS3 comparisons, as 
we predicted greater reductions on the outcome measur s in PA than sham treatment group), 
and two-tailed tests for the remaining comparisons. We controlled for type I errors in the 
primary (but not exploratory) analyses by using Holm-Bonferroni correction for multiple 
comparisons within analysis of each outcome and report d adjusted p values (padj).  
Our primary analysis involved the intention-to-trea population, that is, participants who 








regardless of their treatment adherence or completion of the outcome assessments (PA 
treatment = 23, sham treatment = 26). Note that the rial protocol defined this population as 
all participants allocated to treatment, which did not account for the possibility that they 
could withdraw before being trained in how to carry out their allocated intervention. This was 
the case for three participants (Figure 2) who were not included in the intention-to-treat 
sample as per an updated definition. In Supplemental Text S2 (available at 
http://links.lww.com/PAIN/B162) we report a supportive per-protocol analysis of those 
participants who provided complete outcome data and completed their allocated treatment 
(missed no more than six treatment sessions). The results of the per-protocol analysis are 
broadly consistent with the intention-to-treat analysis. 
2.5.2.1. Effects of PA treatment on the primary outc mes 
To evaluate the effects of PA treatment on the first p imary outcome of pain intensity 
(research question 1) and the time course of any changes (research question 3), we conducted 
a 2 (Group: PA treatment, sham treatment) x 6 (Time: RS1, RS2, RS3, RS4, LTFU1, LTFU2) 
ANOVA. We planned sixteen a-priori contrasts to compare RS1 vs RS2, RS2 vs RS3, RS3 vs 
RS4, RS2 vs RS4, RS2 vs LTFU1, RS4 vs LTFU1, LTFU1 vs LTFU2, and RS2 vs LTFU2 
within each treatment group.  
To evaluate the effects of PA treatment on the second primary outcome of the CRPS severity 
score (research question 1) and the time course of any changes (research question 3), we 
conducted a 2 (Group: PA treatment, sham treatment) x 4 (Time: RS1, RS2, RS3, RS4) 
ANOVA. We planned eight a-priori contrasts to compare RS1 vs RS2, RS2 vs RS3, RS3 vs 








2.5.2.2. Effects of PA treatment on the secondary outcomes 
To evaluate the effects of PA treatment on self-repo ted pain and psychological functioning, 
sensory, motor, and autonomic function, and neuropsychological functions (research question 
2), and the time course of any changes (research question 3), we conducted 2x6 and 2x4 
ANOVAs and planned the same contrasts as described for the analyses of the primary 
outcomes. 
2.5.2.3. Predictors of the CRPS progression over time
To investigate whether any baseline factors could pre ict CRPS progression over time 
(research question 4), independent of the treatment, we used the data from the total sample (N 
= 49) to perform exploratory best subsets regression analyses on the overall change in pain 
intensity and CRPS severity score throughout the course of the study. This analysis differed 
from that proposed in the trial protocol in terms of (a) operationalisation of the pain outcome, 
(b) selection of potential predictors, and (c) regression model used. (a) Change on the primary 
outcomes was quantified as individual regression slpes fitted to each participant’s ratings of 
current pain intensity across RS1-LTFU2 (instead of planned RS1-RS4 comparisons, to 
capture change over a longer period) and to each partici nt’s CRPS severity scores across 
RS1-RS4. More negative slopes indicate greater improvement over time (i.e. reduction in 
pain and CRPS severity). (b) In the protocol, when specifying selection of potential 
predictors we planned to prioritize those factors on which participants with CRPS 
significantly differed from pain-free participants at baseline (research question 5; [34]). 
However, they showed no differences on the tests of neuropsychological functions (results 
reported elsewhere [32]). Thus, we instead included all primary and secondary outcomes as 
potential explanatory variables. That is, we included participants’ demographic 
characteristics, self-reported pain and psychological functioning, sensory, motor, and 








pool of potential predictors by excluding factors that lacked linear relationships with each 
outcome or were collinear with other predictors (see Supplemental Text S1, available at 
http://links.lww.com/PAIN/B162). (c) Instead of the planned linear mixed model regression, 
best subsets regression was deemed more appropriate to allow unbiased selection of the best 
combination of explanatory variables. Best subsets regression is an automated approach that 
performs an exhaustive search for the best subset of fact rs for predicting the outcome and 
returns the best model of each size (up to a specified number of predictors) [56]. Considering 
our sample size (N = 49), we compared best subsets models that included one up to five 
predictors of each outcome. From the five models, the one with the lowest Akaike 
Information Criterion was preferred as best fit. To address a potential issue of overfitting, we 
also performed a five-fold cross-validation [48] of each of the five models suggested by best 
subsets regression analyses. This approach randomly splits the data set into five folds (subsets 
of observations). Each model is trained using the 80% of the data (four folds) and then tested 
on the remaining 20% of the data (one fold). This process is repeated until each fold has 
served as a test subset. The average of errors recorded in each repetition is a cross-validation 
error. The lowest cross-validation error indicates b t model performance.  
 
3. Results 
3.1. Participant characteristics 
Table 1 presents baseline characteristics and comparisons between PA and sham treatment 
groups. On average, participants reported moderate pain intensity (6/10), comparable with 
previous studies on prism adaptation (5.8-6/10; [12,100]) and other neurocognitive treatments 
(5.3-7/10; [45,61,73]) for CRPS. Median CRPS severity score in our sample was higher than 








tool (13 vs. 11.2/16; [37]), possibly because we usd tricter inclusion criteria (Budapest 
research diagnostic criteria; [35]). Our participants on average had longer CRPS duration 
compared to other studies of neurocognitive treatmen s for CRPS (58 vs. 5-24 months; 
[9,12,45,61,73,100]). The proportion of participants with CRPS affecting their right side of 
the body was consistent with a large population study [70], although it was lower than in 
small-sample studies on prism adaptation (41% vs. 71-80%; [12,100]). Both the mean age 
and proportion of females were consistent with those previously reported in CRPS 
[12,37,70,91,100]. The most common comorbidities in our participants were depression 
(37%), anxiety (22%), migraines (16%), fibromyalgia (14%), and asthma (14%). These 
conditions were found to be prevalent in CRPS in previous population studies [52,71]. The 
most common treatments in the current sample included weak or strong opioids (57%), 
anticonvulsants (47%), paracetamol (45%), antidepressants (45%), physio-, hydro-, or 
occupational therapy (39%), and nonsteroidal anti-inflammatory drugs (35%; see 
Supplemental Table S1, available at http://links.lww.com/PAIN/B162). Overall, demographic 
and clinical characteristics of our sample appear to be representative of general population of 
people with CRPS [2,37,70,91] and comparable to those reported in previous research 
investigating neurocognitive treatments for CRPS [9,12,45,61,73,100], except for the longer 
average disease duration in our study.  
The randomization procedure successfully equated th two treatment groups on the 
minimization factors (Table 1). The two groups were also matched on baseline mean levels of 
optimism, mood disturbance, fear of movement, and expectations and criteria for success of 
the treatment (there were no significant differences b tween PA and sham treatment groups 










Eight participants (16%) withdrew from the study following treatment allocation. They were 
excluded from per-protocol analysis (Supplemental Text S2, available at 
http://links.lww.com/PAIN/B162), but their RS2 data w s carried forward for the purpose of 
the primary intention-to-treat analysis. We compared their baseline (RS1) pain intensity and 
CRPS severity against confidence intervals around the mean pain intensity and CRPS 
severity score of participants who remained in the trial. Out of those who dropped out, five 
participants had greater pain intensity and four participants had greater CRPS severity 
compared to those who remained. However, the same or lower pain intensity and CRPS 
severity scores were found in another three and four participants who dropped out, 
respectively.  
3.2. Treatment adherence and participant blinding 
Twenty-one out of 23 participants (91%) in the PA trea ment group and 20 out of 26 
participants (77%) in the sham treatment group missed no more than six treatment sessions 
according to their logbooks (see Supplemental Table S1, available at 
http://links.lww.com/PAIN/B162). Two participants in the PA and six participants in the 
sham treatment group missed more than six treatment sessions and/or did not provide post-
treatment outcome data. No other deviations from the treatment protocol were identified 
among the remaining participants. The extent of exposure to treatment (i.e. average number 
of logged treatment sessions) was not significantly different between the two treatment 
groups (Table 1). The median recorded durations of the treatment sessions according to the 
participants’ logbook entries were 2min 25s in the PA group and 2min in the sham treatment 
group.  
At the end of RS4, we asked each participant (N = 41) which treatment they thought they 








participants in each group made correct (real: 12.2%; sham: 12.2%) or wrong (real: 12.2%; 
sham: 7.3%) guesses as to their actual treatment allocation, or responded that they had no 
idea (real: 26.8%; sham: 29.3%), χ2(2) = .52, p = .771, Cramer’s V = 0.11. Only 12% of 
participants in each group correctly guessed their r atment allocation, therefore participant 
blinding was successful. 
3.3. Effects of PA treatment on the primary outcomes 
Figure 4 illustrates any changes on the primary outcomes and their time course in each 
treatment group (research questions 1 and 3). Despite the PA group showing some reduction 
in the current pain intensity scores immediately after treatment (RS3; Figure 4a), the 
ANOVA did not reveal any significant main effects of Time, F(4.04, 189.81) = 1.82, p = 
0.126, ƞ2p = 0.04, or Group, F(1, 47) = 0.26, p = 0.615, ƞ
2
p = 0.01, nor did it show any 
significant interaction between these factors F(4.04, 189.81) = 0.66, p = 0.624, ƞ2p = 0.01. 
This indicates that there were no significant changes in pain intensity over time in either 
treatment group. Thus, contrary to our hypothesis, PA treatment did not reduce pain intensity 
more than sham treatment.  
Analysis of the CRPS severity scores (Figure 4b) showed a large significant main effect of 
Time, F(2.28, 107.08) = 17.57, p < .001, ƞ2p = 0.27, indicating that regardless of treatment, 
CRPS severity decreased over time (Figure 4b). Contrasts revealed a significant reduction in 
CRPS severity immediately after treatment (RS3; Mdn = 11.00, BCa 95% CI [11.00, 11.00]) 
compared to immediately before treatment (RS2; Mdn = 12.00, BCa 95% CI [12.00, 12.00]), 
Z = -3.91, padj = .002, d = 0.86. This reduction relative to RS2 was maintained four weeks 
after completing the treatment (RS4; Mdn = 11.00, BCa 95% CI [11.00, 11.00]), Z = -3.70, 
padj = .002, d = 0.81, but without further significant change from RS3, Z = -0.81, padj = .433, 








BCa 95% CI [13.00, 13.00]) and the second baseline session, Z = -1.71, padj = .170, d = 0.35. 
There was no significant effect of Group, F(1, 47) = 0.17, p = .685, ƞ2p < 0.01, nor was there 
any significant interaction effect, F(2.28, 107.08) = 0.17, p = .886, ƞ2p < 0.01, on the CRPS 
severity scores. Thus, contrary to our hypothesis, CRPS severity did not decrease more 
following PA compared to sham treatment, but both groups improved over the treatment 
period. 
[Figure 4] 
We compared mean changes in pain intensity and CRPS severity over the treatment period 
(RS3 – RS2) between PA and sham treatment groups. Effect sizes of these differences might 
be important for planning future studies. For current pain intensity, the effect size was small, 
d = 0.37, 95% CI [-0.20, 0.94]. Mean pain reduction in the PA treatment group was -0.78 
points on 0-10 NRS scale, BCa 95% CI [-1.55, -0.15]. In the sham treatment group, mean 
pain reduction was -0.19 points, BCa 95% CI [-0.68, 0.28]. For CRPS severity score, the 
effect size was negligible, d = -0.13, 95% CI [-0.69, 0.43]. Mean CRPS severity reduction in 
the PA treatment group was -0.78 points on 0-16 scale, BCa 95% CI [-1.19, -0.38]. In the 
sham treatment group, the mean CRPS severity reduction was -0.96 points, BCa 95% CI [-
1.54, -0.38]. On an individual level (Supplemental Figure S1, available at 
http://links.lww.com/PAIN/B162), five participants in the PA group and four in the sham 
group achieved clinically significant reductions in pain (i.e. at least two-point decrease on 0-
10 NRS scale [20]) over the treatment period. None f the participants achieved clinically 
significant reduction in CRPS severity (i.e. at least 4.9 points decrease on 0-16 scale, 








3.4. Effects of PA treatment on the secondary outcomes 
Group average scores on the self-report questionnaires, clinical assessments, and 
neuropsychological tasks in each time point are report d in Table 2. Note that the confidence 
intervals around average baseline indices of the neuropsychological functions include zero, 
indicating that participants did not show significant biases in visuospatial attention or the 
mental representation of space, nor any differences in the recognition of the affected relative 
to unaffected hands. Furthermore, average indices of directional hypokinesia and 
bradykinesia vary between positive and negative values, suggesting that there were no 
systematic spatially-defined motor deficits at baseline. Complete results of a series of 
ANOVAs conducted to test the effects of PA on the secondary outcomes and their time 
course (research questions 2 and 3) are reported in the tables, and below we only refer to the 
effects directly relevant for our hypothesis, that is, Group x Time interactions. 
[Table 2] 
Results of 2x6 ANOVAs on the self-reported pain-relat d, body representation, and 
emotional functioning outcomes, and 2x4 ANOVAs on the sensory, motor, autonomic, and 
neuropsychological functions, are reported in Table 3. Among these outcomes, the 
Mechanical Detection Threshold, Mechanical Pain Thres old, Two-Point Discrimination 
threshold, grip strength, and delta finger-to-palm distance ratios data, the Landmark task, and 
spatially-defined motor function data were analysed using linear mixed models regression 
due to severe violations of normality, homogeneity of variance, and/or sphericity 










Contrary to our hypothesis, we found no evidence of significantly greater reductions in self-
reported CRPS-related and psychological disturbances; or sensory, autonomic, and motor 
impairments following PA compared to sham treatment. We also did not find any 
significantly greater reductions in biases in spatial cognition, motor control, and body 
representation following PA compared to sham treatmnt. That is, most interactions between 
treatment group and time on these outcomes were not significant, and any effects revealed by 
the planned contrasts following the few significant interactions did not withstand correction 
for multiple comparisons. These effects are further elaborated below. A significant 
interaction on the Bath CRPS Body Perception Disturbance scores appeared to be due to 
reductions in body perception disturbance following the PA treatment, s ≤ 2.86, psadj ≥ .336, 
ds ≤ 0.54. A significant interaction on the Tampa Scale for Kinesiophobia sores appeared to 
be driven by reductions in fear of movement following the sham treatment, ts ≤ 2.63, psadj ≥ 
.312, ds ≤ 0.26. A significant interaction on the Mechanical P in Threshold ratios seemed to 
be due to a reduction in hyperalgesia over the treatm nt period in the PA group, Zs ≤ 1.68, 
psadj ≥ .440, ds ≤ 0.51. All these effects were no longer significant fter Holm-Bonferroni 
correction and there were no other significant interactions. On average, participants in both 
treatment groups perceived their symptoms to be either “almost the same”, or “a little better” 
(2-3 out of 7 on the Patients’ Global Impression of Change) at each post-treatment time-
point.  
The PA and sham treatment groups also did not differ on their average daily logbook ratings 
of pain intensity, symptoms interference, and range of movement at any time point [pain 
intensity: ts(45) ≤ 1.75, ps ≥ .093, ds ≤ 0.51; symptom interference: ts(45) ≤ 1.24, ps ≥ .240, 
ds ≤ 0.36; range of movement: ts(45) ≤ 1.81, ps ≥ .062, ds ≤ 0.53]. The planned analyses of 
the number of days to reach peak improvement and from peak improvement to return to 








the absence of treatment effects, but logbook ratings for each group are illustrated in 
Supplemental Figure S2 (available at http://links.lww.com/PAIN/B162). 
Overall, our analyses did not reveal any significant effects of PA compared to sham treatment 
on any of the secondary outcome measures.  
3.5. Predictors of CRPS progression over time  
Since there was no effect of treatment on the primary outcomes, we did not explore potential 
predictors of the response to PA treatment as proposed in the trial protocol [34]. However, to 
explore whether the absence of the PA effect could be explained by the lack of group-level 
neuropsychological deficits in our sample, we visuali ed individual relationships between the 
changes on the primary outcomes over the treatment period and baseline spatial bias and 
body representation distortion in Supplemental Figures S4 and S5, respectively (available at 
http://links.lww.com/PAIN/B162). Overall, there were no apparent clusters of participants or 
relationships between these factors. Subgroup analyses of whether response to treatment 
depended on clinical phenotypes of CRPS [16] or baseline neuropsychological differences 
are also reported in Supplemental Text 3 (available t http://links.lww.com/PAIN/B162), 
showing results consistent with the primary analyses. 
To address research question 4 about the predictors of CRPS progression over time, we 
explored which baseline factors (RS1) could predict overall change in pain intensity (across 
RS1-RS4 and LTFU1-LTFU2) and CRPS severity (across RS1-RS4). Table 5 summarises 
the models identified via best subsets regression analyses, and their respective values of our 
model selection criteria (the lowest Akaike Information Criteria and cross-validation errors 
indicating the best models). Greater reduction in pai  intensity was best predicted by smaller 
change in hand preference since CRPS onset (absolute change on the Edinburgh Handedness 








Greater reduction in CRPS severity was best predict by lower pain intensity (t = 3.69, p < 
.001, ß = 0.52), less swelling of the affected limb (t = 2.52, p = .015, ß = 0.37), and more 
accurate recognition of images of the affected hand (i.e. smaller Hand laterality recognition 
accuracy index; t = 2.43, p = .019, ß = 0.32), as measured at baseline (RS1), in a three-factor 




The results from this double-blind, randomized, sham-controlled trial do not support the 
effectiveness of PA treatment for upper-limb CRPS-I. First, we found no evidence that two 
weeks of twice-daily PA treatment performed with the affected arm reduced the primary 
outcomes of current pain intensity or symptom severity more than sham treatment in long-
standing CRPS. Second, we found no evidence that PA affected the secondary outcomes of 
self-reported CRPS-related and psychological functio ing; sensory, motor, and autonomic 
signs; or spatial cognition, motor function, and body representation.  
Our findings contradict the conclusions of previous studies that PA could relieve pain and 
other CRPS symptoms. In the first of these, two weeks of once-daily PA training resulted in 
50% pain relief, and reduced oedema and skin discoloration in five people with CRPS [100]. 
In the second study, three weeks of daily PA effectiv ly resolved one patient’s pain, reduced 
autonomic symptoms, and improved motor function [9]. In the third study, four days of 
twice-daily PA resulted in 36% pain relief in seven people with CRPS [12]. In the two latter 
studies, its effects on pain were maintained for up to two weeks after discontinuing the 
treatment. While addressing the limitations of these preliminary small-sample, uncontrolled, 








beyond those of a control treatment. A small reduction in pain intensity immediately 
following PA (13% reduction) was not significantly greater than after sham treatment (3%). 
Similarly, there was an overall reduction in CRPS severity immediately after treatment that 
persisted for four weeks, but was present in both PA (7%) and sham (8%) treatment 
groups. Although a lack of evidence for superiority of PA relative to sham treatment does not 
prove their equivalence, the effect sizes of any differences were negligible to small. 
Consistent across per-protocol and intention-to-treat analyses, there is no evidence that PA is 
any more effective than sham treatment for CRPS. 
The decrease in CRPS severity across both treatment groups could be explained by a placebo 
effect and/or general benefits of moving the affected limb. Meta-analyses of clinical trials 
found that placebo response can correspond to an 1.84-point immediate post-treatment 
reduction in CRPS pain [60], or a 0.65-point reduction in chronic pain generally (on a 0-10 
scale) [39]. This effect might also be responsible for the reduction in CRPS severity in our 
trial. Increased movement of the affected limb is alikely alternative explanation, because all 
participants performed the pointing task with their affected hand, regardless of the treatment 
condition. Physical exercise is a core pillar of CRPS management [28], and this additional 
daily activity might have been sufficient to reduce CRPS severity. It is unlikely that the 
observed changes were due to natural recovery, which might occur within the first year from 
diagnosis [1], as participants were on average diagnosed with CRPS for five years. Disease 
duration was also unrelated to changes in pain intesity or CRPS severity (Supplemental 
Figure S3, available at http://links.lww.com/PAIN/B162). Regression to the mean cannot 
fully account for the decrease in CRPS severity, as no changes occurred over the baseline 
period. Overall, our findings reinforce the importance of including control treatment arms in 









We address three potential reasons why we did not fi d the hypothesised effects of PA on 
clinical outcomes: (1) non-central pathophysiology f CRPS, (2) absence of 
neuropsychological symptoms, and (3) trial limitations. First, because PA targets 
neuropsychological deficits, it would possibly be most appropriate for a subset of individuals 
who predominately show signs of central neuroplasticity (compared to peripheral 
inflammation) [5,16]. However, post-hoc classificaton of participants into central or 
peripheral phenotypes and follow-up exploratory subgroup analysis did not reveal different 
responses to PA versus sham treatment (Supplemental Table S1 and Text S3, available at 
http://links.lww.com/PAIN/B162).  
Second, it is possible that we found no effect of PA on participants’ spatial cognition or body 
representation because, in contrast to previous findings [11,21,25,27,76,84,85,94,99], they 
did not have any systematic deficits on baseline experimental measures of spatial cognition 
and body representation. One hypothesised mechanism of the apparent benefits of PA in 
previous CRPS studies is that it reduces pain by corre ting the “neglect-like” bias away from 
the affected side. A potential second mechanism is based on the proposal that distorted body 
representation gives rise to discrepancies between anticipated and actual consequences of 
movement, which cause or exacerbate pain in conditis such as CRPS [8,38,61,62]. The 
transient sensorimotor incongruence introduced by wearing prisms is thought to provide an 
error signal that triggers normalisation of body representation and sensorimotor integration 
[9,100]. On average, our participants showed balanced distributions of spatial attention and 
spatial representations, no systematic slowing of movements directed towards the affected 
side, and unimpaired laterality recognition of images of affected hands at baseline (see Table 
2 and [32]). Cognitive after-effects of PA have been shown to depend on baseline spatial bias 
[14,29,44]. Therefore, if altering spatial cognition and/or body representation were integral 








neuropsychological deficits could preclude any effects of PA on the primary clinical 
outcomes. However, we dismiss this explanation, based on the following reasons. In the 
follow-up exploratory analyses, we found no relationships between the extent of baseline 
spatial or body representation deficits and changes in the primary outcomes over the 
treatment period (Supplemental Figures S4 and S5, available at 
http://links.lww.com/PAIN/B162). We also found no evidence that PA benefitted subgroups 
of individuals who did present with “neglect-like” symptoms or distorted representation of 
the affected limb (Supplemental Text S3, available at http://links.lww.com/PAIN/B162). 
Furthermore, Christophe et al. [12] reported reduce CRPS pain after PA in the absence of 
any baseline spatial deficits, and without any effect on spatial cognition or motor control. 
Finally, Sumitani et al. [100] found a significant reduction in pain post-treatment, and a 
simultaneous shift in the coding of external spatial information relative to the body away 
from the affected side (i.e. direction opposite to the expected PA spatial after-effects). Since 
these previous studies [12,100] had no control treatm nt arms, the apparent benefits of PA 
could be due to other non-specific factors. Nonethel ss, overall it seems that response to PA 
treatment is unrelated to “neglect-like” spatial bias or body representation distortion. 
Third, we considered several limitations of our study that might explain why we did not find 
the hypothesised effects of PA. Since we tested a protocol of PA that could realistically be 
integrated into CRPS management as a self-administered, home-based treatment, we cannot 
rule out compliance violations. We relied solely upon participants’ self-reported adherence, 
therefore the lack of apparent difference between th  effects of PA and sham treatment could 
be due to deviations from the instructed treatment protocol. However, previous CRPS studies 
reported symptom improvement following less frequent [100], fewer [12], and home-based 
[9] PA sessions. PA protocols similar to ours using sufficiently strong prisms (10-20°) and 10 








neglect [24,95]. Our use of home-based treatments meant that it was not feasible to confirm 
adaptation by measuring pointing after-affects. Yet pr vious studies using 50 pointing 
movements have shown that this is sufficient to create after-effects [9,90,100]. Overall, we do 
not consider that these limitations provide reason to doubt our findings that PA is not an 
effective treatment for long-standing CRPS. Nonethel ss, greater confidence could be gained 
from a trial of supervised PA with a greater number of sessions, and confirmed adaptation. 
Similarly, acute patients, in whom symptoms are less established, might yet benefit from PA. 
This longitudinal study allowed us to explore potential baseline predictors of CRPS 
progression over 10-30 weeks, regardless of treatment. Smaller change in hand preference 
since CRPS onset predicted greater reduction in pain intensity. Consistent with the learned 
non-use hypothesis [80], underutilization of CRPS-affected limb and compensatory use of the 
unaffected extremity might maintain CRPS symptoms and hinder recovery. Overall reduction 
in CRPS severity was predicted by smaller pain intensi y and oedema of the affected limb, 
suggesting that people with milder symptoms are likly to improve more. Individuals who 
were better at recognising images of affected relative to unaffected hands also achieved 
greater reduction in CRPS severity. Body perception disturbance was previously linked to 
longer CRPS duration and more severe sensory and motor signs of CRPS [46,50,105]. Our 
findings that less distorted representation and maintained use of the affected limb predict 
greater symptom improvement support multidisciplinary pain management approaches, 
which aim to normalise body representation and foster active movement [28,73,74]. These 
interpretations are, however, tentative, as the analyses were exploratory and the 
abovementioned factors explained only 9% and 25% of variance in the overall changes in 
pain intensity and CRPS severity, respectively.   
We conclude that there is no evidence that PA reducs pain and other symptoms more than 








likely due to the placebo effect, greater movement of the affected limb, regression to the 
mean, and/or natural recovery.  
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Figure legends 
Figure 1. Schedule of data collection and interventions.  
Figure 2. CONSORT diagram. Flow of participants through the study. RS1, research session 
1; RS2, research session 2; RS3, research session 3; RS4, research session 4; LTFU1, long-
term follow-up 1; LTFU2, long-term follow-up 2; Intention-to-treat analysis, participants 
who received allocated intervention; Per-protocol analysis, participants who completed 








participants who were allocated to Prism adaptation treatment did not attend RS2 or did not 
meet the eligibility criteria in RS2, thus they were not trained and did not receive any 
treatment, and were not included in the intention-t-treat analysis. 
Figure 3. Prism adaptation procedure. In this example, participant with left-CRPS is using 
rightward-shifting prisms (A-C), which induce adapttion towards the left (affected) side. For 
clarity of illustration, only one target (red circle) is represented in the figure. However, the 
treatment procedure involved two targets presented i  the left and right side of space, and 
participants’ pointing movements alternated between th  left and right targets. (A) Prism 
goggles shift visual image to the right. Blue triangle represents a shift of visual perspective 
and perceived target location (pale red circle), relative to real location of the target (light grey 
triangle, dark red circle). (B) Pointing movements i itially err to the right. (C) Adaptive 
realignment results in correct pointing movements. (D) Goggles are removed and pointing 
movements err to the left (after-effect).  
Figure 4. Primary outcomes (intention-to-treat analysis). Mean [BCa 95% CI] current pain 
intensity (A) and CRPS severity scores (B) in prism adaptation (PA; orange circles) and sham 
treatment (blue diamonds) groups in each time point. RS1, RS2, RS3, and RS4, research 
sessions 1, 2, 3, and 4; LTFU1 and LTFU2, long-term follow-up 1 and 2. Grey arrows 
indicate the treatment period. **Significant decreas  in CRPS severity between RS2 and 
RS3, maintained at RS4, regardless of treatment, ps
adj





Table 1 Baseline (RS1) participant characteristics by treatment group (intention-to-treat analysis) 
Measure Prism adaptation 
treatment (n = 23) 
Sham treatment  
(n = 26) 
Contrast 
Minimisation factors    
Current pain intensity (/10) M 5.96 [5.02, 6.80] 6.15 [5.26, 7.00] t(47) = -0.33, p = .741, d = 
0.10 
CRPS severity score (/16) Mdn 13.00 [12.07, 13.93] 12.50 [11.00, 13.00] U = 287.50, p = .809, d = 0.07 
Primarily affected arm (% right) 48% 35% χ2(1) = .88, p = .348, ϕ = -0.13 
Pre-CRPS dominant hand (% 
right) 
91% 92% χ2(1) = .16, p = .898, ϕ = 0.02 
Sex (% female) 83% 85% χ2(1) = .04, p = .850, ϕ = -0.03 
Age (years) M 47.35 [43.20, 51.95] 45.31 [39.85, 50.85] t(47) = 0.53, p = .601, d = -
0.15 
CRPS in other body parts (% 
present) 
13% 8% χ2(1) = .38, p = .537, ϕ = -0.09 
Other non-CRPS pain (% present) 44% 39% χ2(1) = .13, p = .721, ϕ = -0.05 
CRPS duration (months since 
diagnosis) M 
61.26 [47.15, 75.12] 52.31 [39.49, 66.35] t(47) = 0.84, p = .388, d = -
0.24 
Other control measures    
Optimism (Revised Life 
Orientation Test; /24) M 
13.00 [10.97, 15.07] 12.31 [11.00, 13.61] t(47) = 0.59, p = .560, d = -
0.17 
Mood disturbance (Profile of 
Mood States; /229) M 
94.81 [79.96, 109.93] 84.22 [70.94, 98.08] t(47) = 0.97, p = .349, d = -
0.28 
Fear of movement (Tampa Scale 
for Kinesiophobia; /68) M 
38.79 [35.45, 41.95] 40.38 [37.17, 43.35] t(47) = -0.65, p = .502, d = 
0.19 
Number of logged treatment 
sessions (/29) Mdn 
29.00 [28.54, 29.46] 29.00 [28.55, 29.45] U = 297.00, p = .965, d = 0.01 
Bootstrapped bias-corrected and accelerated 95% confidence intervals are reported in square brackets, [BCa 95% CI].  






Table 2 Mean or median values [BCa 95% CI] of self-reported; sensory, autonomic, and motor; and neuropsychological secondary outcome measures at 
each time point (intention-to-treat analysis) 
Measure Group Time point      
  RS1 RS2 RS3 RS4 LTFU1 LTFU2 
Self-report questionnaires 
Pain  
Pain severity (Brief Pain 
Inventory; /10) M 
PA 5.91 [5.17, 6.58] 6.02 [5.28, 6.71] 5.41 [4.50, 6.26] 5.43 [4.55, 6.24] 5.62 [4.69, 6.48] 5.59 [4.69, .41] 
Sham 5.81 [5.02, 6.50] 5.95 [5.12, 6.78] 5.85 [5.04, 6.65] 5.84 [4.82, 6.74] 6.04 [5.12, 6.80] 5.95 [5.07, 6.73] 
Pain interference (Brief Pain 
Inventory; /10) Mdn 
PA 6.71 [6.29, 6.71] 6.43 [5.00, 7.08] 5.29 [3.57, 6.43] 5.57 [4.71, 6.29] 6.00 [5.22, 6.14] 5.86 [4.57, 6.86] 
Sham 5.79 [5.00, 7.14] 5.86 [5.72, 5.86] 5.57 [5.43, 5.57] 5.64 [4.00, 6.14] 5.50 [3.71, 6.57] 5.72 [4.14, 6.57] 
Neuropathic features of pain 
(Pain Detect Questionnaire; 
/38) Mdn 
PA 26.00 [26.00, 26.00] 25.00 [20.00, 26.00] 24.00 [21.00, 27.00] 24.00 [20.00, 26.00] 26.00 [25.00, 26.00] 26.00 [21.46, 28.00] 
Sham 23.50 [21.50, 27.00] 24.00 [23.00, 24.00] 23.50 [20.00, 26.00] 22.50 [17.06, 26.00] 23.00 [20.00, 25.00] 22.50 [18.00, 26.00] 
Body representation 
Bath CRPS Body Perception 
Disturbance Scale (/57) M
PA 27.65 [22.83, 32.34] 27.78 [24.00, 31.22] 22.13 [17.88, 26.44] 24.39 [20.48, 28.57] 25.52 [21.78, 29.30] 24.57 [20.91, 28.44] 
Sham 28.96 [23.96, 33.76] 27.73 [21.98, 33.92] 29.00 [23.00, 35.36] 26.81 [20.92, 33.61] 26.77 [21.48, 32.68] 27.65 [22.53, 33.28] 
Emotional functioning 
Fear of movement (Tampa 
Scale for Kinesiophobia; 
/68) M 
PA 38.79 [35.45, 41.95] 38.52 [35.02, 41.73] 37.43 [34.26, 40.50] 37.91 [34.70, 41.17] 38.74 [35.33, 41.95] 40.05 [36.22, 43.71] 






Measure Group Time point      
  RS1 RS2 RS3 RS4 LTFU1 LTFU2 
Mood disturbance (Profile of 
Mood States; /229) M 
PA 94.81 [79.96, 109.93] 98.25 [82.66, 113.93] 86.52 [71.16, 100.10] 86.21 [73.85, 99.00] 88.80 [74.42, 103.51] 95.54 [73.56, 117.95] 
Sham 84.22 [70.94, 98.08] 91.27 [76.05, 106.01] 83.21 [68.95, 96.96] 83.35 [68.76, 97.56] 82.42 [68.05, 96.53] 89.13 [70.81, 106.31] 
Perceived improvement due to treatment 
Patient’s Global Impression 
of Change (/7) Mdn 
PA - - 2.00 [2.00, 4.00] 3.00 [3.00, 3.00] 2.00 [2.00, 4.00] 3.00 [2.00, 3.00] 




Threshold ratio Mdn 
PA -0.04 [-0.43, 0.38] -0.35 [-1.12, 0.17] -0.44 [-0.84, -0.06] -0.54 [-1.51, -0.10] - - 
Sham -0.30 [-1.37, 0.24] -0.05 [-0.25, 0.17] -0.14 [-0.91, 0.30] -0.22 [-0.76, 0.28] - - 
Mechanical Pain Threshold 
ratio Mdn 
PA 0.62 [0.06, 0.69] 0.50 [0.43, 0.56] 0.07 [-0.32, 0.66] 0.50 [0.06, 0.69] - - 
Sham 0.57 [0.24, 0.67] 0.56 [0.38, 0.73] 0.50 [0.32, 0.71] 0.43 [0.24, 0.78] - - 
Allodynia (/100) Mdn PA 14.00 [5.76, 26.67] 18.87 [4.67, 30.89] 16.90 [6.00, 26.17] 10.73 [2.87, 18.26] - - 
Sham 20.50 [9.00, 33.83] 14.37 [6.47, 25.03] 13.87 [6.47, 46.47] 18.03 [7.33, 33.33] - - 
Two-Point Discrimination 
threshold ratio Mdn 
PA -0.06 [-0.16, 0.11] 0.00 [-0.08, 0.13] -0.08 [-0.2 , 0.00] -0.04 [-0.21, 0.03] - - 
Sham 0.15 [-0.07, 0.31] -0.13 [-0.25, 0.10] -0.09 [-0.17, 0.00] 0.05 [-0.30, 0.22] - - 
Autonomic functions 
Absolute temperature 
difference (°C) Mdn 
PA 0.47 [0.27, 1.40] 0.30 [0.14, 0.68] 0.35 [0.20, 0.73] 0.50 [0.17, 1.17] - - 
Sham 0.47 [0.30, 0.78] 0.82 [0.53, 1.07] 0.77 [0.43, 1.05] 0.67 [0.40, 1.00] - - 






Measure Group Time point      
  RS1 RS2 RS3 RS4 LTFU1 LTFU2 
Sham -0.11 [-0.51, 0.34] -0.02 [-0.40, 0.38] -0.12 [-0.52, 0.30] 0.04 [-0.33, 0.43] - - 
Motor functions 
Grip strength ratio Mdn PA 0.35 [0.17, 0.39] 0.31 [0.25, 0.44] 0.35 [0.30, 0.46] 0.39 [0.30, 0.46] - - 
Sham 0.32 [0.20, 0.65] 0.33 [0.18, 0.58] 0.44 [0.26, 0. 0] 0.42 [0.23, 0.60] - - 
Delta finger-to-palm distance 
ratio Mdn 
PA 0.70 [0.60, 0.88] 0.67 [0.61, 0.87] 0.73 [0.63, 0.84] 0.79 [0.70, 0.82] - - 
Sham 0.69 [0.55, 0.90] 0.72 [0.53, 0.88] 0.79 [0.53, 0.89] 0.77 [0.60, 0.93] - - 
Experimental tests of neuropsychological functions 
Visuospatial attention 
Temporal Order Judgement 
task (Point of Subjective 
Simultaneity; ms) Mdn 
PA 0.16 [-13.82, 9.02] -3.26 [-14.51, 8.35] -1.00 [-8.65, 9.71] 5.18 [-1.74, 10.87] - - 
Sham -0.05 [-7.40, 7.06] -0.75 [-8.55, 6.65] 1.17 [-6.16, 7.33] -2.12 [-10.48, 6.07] - - 
Landmark task (Point of 
Subjective Equality; °) Mdn 
PA 0.04 [-0.20, 0.28] 0.09 [-0.01, 0.19] 0.03 [-0.09, .40] -0.02 [-0.13, 0.19] - - 
Sham 0.06 [-0.07, 0.21] 0.06 [-0.12, 0.17] -0.05 [-0.09, 0.10] 0.05 [-0.04, 0.10] - - 
Greyscales task M PA 0.17 [-0.07, 0.41] 0.12 [-0.11, 0.34] 0.08 [-0.13, 0.30] 0.11 [-0.12, 0.34] - - 
Sham 0.09 [-0.08, 0.26] 0.12 [-0.08, 0.32] 0.07 [-0.10, 0.25] 0.14 [-0.06, 0.31] - - 
Mental representation of space 
Mental Number Line 
Bisection task M 
PA -0.06 [-0.76, 0.67] -0.10 [-0.73, 0.54] 0.04 [-0.58, 0.63] -0.06 [-0.55, 0.42] - - 
Sham 0.12 [-0.51, 0.77] 0.24 [-0.50, 0.99] 0.39 [-0.36, 1.21] 0.31 [-0.34, 0.99] - - 






Measure Group Time point      
  RS1 RS2 RS3 RS4 LTFU1 LTFU2 
Directional hypokinesia, 
affected hand, Index A (ms) 
Mdn 
PA -4.88 [-41.02, 29.55] -2.23 [-40.87, 16.76] -15.41 [-58.35, -9.44] -21.93 [-40.85, -9.44] - - 
Sham -15.65 [-79.21, 26.94] 21.51 [-21.38, 56.06] -24.31 [-61.88, -
12.51] 
-12.26 [-47.44, 16.73] - - 
Directional hypokinesia, 
affected hand, Index B (ms) 
Mdn 
PA -37.53 [-90.19, 16.61] -25.46 [-84.04, 13.63] -48.49 [-80.33, -
22.88] 
4.10 [-40.19, 10.67] - - 
Sham -40.43 [-48.52, -
21.96] 
-0.40 [-61.60, 15.61] -8.19 [-48.87, 13.72] 3.32 [-43.06, 20.37] - - 
Directional hypokinesia, 
unaffected hand, Index A 
(ms) Mdn 
PA 0.14 [-15.93, 19.88] 10.28 [1.15, 22.22] -6.76 [-19.29, 13.43] -2.78 [-45.45, 13.43] - - 
Sham 5.57 [-24.54, 26.03] -7.88 [-20.59, 14.27] 6.88 [-15.63, 18.92] 2.51 [-13.48, 23.38] - - 
Directional hypokinesia, 
unaffected hand, Index B 
(ms) Mdn 
PA 4.84 [-6.43, 11.89] 9.41 [-17.73, 25.19] -3.40 [-21.35, 33.52] 7.43 [-26.43, 38.21] - - 
Sham -23.63 [-48.34, 12.93] 9.18 [-12.92, 28.54] 11.0  [-10.84, 28.46] 16.47 [-2.91, 26.35] - - 
Directional bradykinesia, 
affected hand, Index A (ms) 
Mdn 
PA 97.95 [23.29, 216.69] 64.71 [22.36, 123.85] 46.11 [14.19, 72.77] 52.74 [22.18, 66.01] - - 
Sham 3.73 [-32.67, 67.35] 50.72 [-5.50, 64.21] 31.79 [3.63, 87.48] 41.09 [11.92, 64.21] - - 
Directional bradykinesia, 
affected hand, Index B (ms) 
Mdn 















Measure Group Time point      
  RS1 RS2 RS3 RS4 LTFU1 LTFU2 
57.28] 54.09] 17.51] 48.41] 
Directional bradykinesia, 
unaffected hand, Index A 
(ms) Mdn 
PA 48.80 [35.53, 64.67] 69.36 [35.74, 103.71] 79.01 [45.24, 99.85] 79.78 [59.27, 116.99] - - 
Sham 86.46 [54.45, 127.39] 69.84 [24.68, 113.96] 84.79 [76.26, 86.26] 48.80 [35.53, 64.67] - - 
Directional bradykinesia, 
unaffected hand, Index B 
(ms) Mdn 
PA 31.39 [-13.35, 64.92] 69.35 [25.05, 98.88] 36.70 [21.07, 63.50] 20.37 [-13.72, 66.72] - - 
Sham -28.35 [-71.98, 41.21] 3.34 [-39.16, 44.61] 28.60 [6.71, 53.45] 3.38 [-22.98, 12.57] - - 
Body representation 
Hand laterality recognition, 
accuracy index (%) M 
PA -1.65 [-5.66, 2.34] -2.26 [-5.68, 1.43] 1.30 [-2.23, 4.37] 1.57 [-2.70, 6.00] - - 
Sham 2.77 [-1.32, 7.37] -1.77 [-5.83, 2.21] 3.92 [0.19, 7.72] 2.54 [-2.00, 6.83] - - 
Hand laterality recognition, 
reaction time index (ms) M 























Table 3 Analysis of variance results for secondary outcome measures (intention-to-treat analysis) 
Measure Effect df† F p ƞ2p 
Self-report questionnaires 
Pain severity (Brief Pain 
Inventory) 
Time 4.12, 193.81 1.24 0.295 0.03 
Group 1, 47 0.19 0.664 < 0.01 
Time x Group 4.12, 193.81 1.06 0.379 0.02 
Pain interference (Brief Pain 
Inventory) 
Time* 2.88, 135.32 2.84 0.043 0.06 
Group 1, 47 0.04 0.838 < 0.01 
Time x Group 2.88, 135.32 0.74 0.526 0.02 
Neuropathic features of pain 
(Pain Detect Questionnaire) 
Time* 3.29, 154.50 3.32 0.018 0.07 
Group 1, 47 0.32 0.574 0.01 
Time x Group 3.29, 154.50 0.61 0.625 0.01 
Bath CRPS Body Perception 
Disturbance Scale 
Time 3.41, 160.11 2.43 0.059 0.05 
Group 1, 47 0.57 0.455 0.01 
Time x Group* 3.41, 160.11 2.60 0.047 0.05 
Fear of movement (Tampa 
Scale for Kinesiophobia) 
Time 3.86, 181.61 2.41 0.053 0.05 
Group 1, 47 < 0.01 0.993 < 0.01 
Time x Group* 3.86, 181.61 2.89 0.025 0.06 
Mood disturbance (Profile of 
Mood States) 
Time 3.60, 169.21 2.29 0.069 0.05 
Group 1, 47 0.36 0.554 0.01 
Time x Group 3.60, 169.21 0.25 0.894 0.01 
Patient’s Global Impression 
of Change 
Time 3, 120 0.96 0.414 0.02 
Group 1, 40 0.02 0.890 < 0.01 
Time x Group 3, 120 0.56 0.644 0.01 
Clinical assessments 
Allodynia (affected limb) Time 2.23, 104.67 1.03 0.367 0.02 
Group 1, 47 0.25 0.616 0.01 
Time x Group 2.23, 104.67 0.35 0.730 0.01 
Absolute temperature 
difference 
Time 3, 141 0.43 0.731 0.01 
Group 1, 47 0.16 0.695 < 0.01 
Time x Group 3, 141 0.63 0.595 0.01 






Measure Effect df† F p ƞ2p 
Group 1, 47 0.06 0.805 < 0.01 
Time x Group 2.41, 113.08 1.86 0.153 0.04 
Experimental tests of neuropsychological functions 
Temporal Order Judgement 
task (Point of Subjective 
Simultaneity) 
Time 1.70, 79.69 1.08 0.335 0.02 
Group 1, 47 0.16 0.692 < 0.01 
Time x Group 1.70, 79.69 0.63 0.512 0.01 
Greyscales task Time 2.17, 101.82 0.57 0.581 0.01 
Group 1, 47 0.02 0.899 < 0.01 
Time x Group 2.17, 101.82 0.52 0.609 0.01 
Mental Number Line 
Bisection task 
Time 2.39, 112.17 0.48 0.656 0.01 
Group 1, 47 0.50 0.481 0.01 
Time x Group 2.39, 112.17 0.14 0.899 < 0.01 
Hand laterality recognition, 
Accuracy index 
Time 3, 141 2.39 0.072 0.05 
Group 1, 47 1.54 0.221 0.03 
Time x Group 3, 141 0.44 0.723 0.01 
Hand laterality recognition, 
Reaction time index 
Time 3, 141 1.32 0.269 0.03 
Group 1, 47 0.05 0.826 < 0.01 
Time x Group 3, 141 1.48 0.224 0.03 
* Statistically significant effect (p < .05). 






Table 4 The results of the bootstrapped linear mixed models regressions of scores for the tests of sensory and motor function, visuospatial attention, and 
spatially-defined motor function (intention-to-treat analysis) 
Model term Coefficient estimate [95% CI] 
 Sensory functions Motor functions Visuospatial 
attention 
  











(Point of Subjective 
Equality) 
  
Intercept -1.27 [-1.96, -0.64]* 0.17 [-0.12, 0.45] -0.04 [-0.16, 0.07] 0.39 [0.35, 0.43]* 0.71 [0.65, 0.76]* 0.13 [0.02, 0.24]*   
Time (RS2 = 0) 
RS1 -0.40 [-1.99, 1.05] -0.44 [-0.99, 0.07] -0.02 [-0.21, 0.15] -0.03 [-0.08, 0.01] -0.04 [-0.12, 0.03] 0.09 [-0.18, 0.38]   
RS3 -0.26 [-1.29, 0.69] -0.49 [-1.00, -
0.07]* 
-0.14 [-0.31, 0.03] 0.01 [-0.05, 0.06] -0.02 [-0.11, 0.06] 0.06 [-0.09, 0.21]   
RS4 -0.58 [-1.83, 0.48] -0.14 [-0.51, 0.24] -0.04 [-0.21, 0.13] 0.03 [-0.03, 0.09] 0.03 [-0.04, 0.10] -0.02 [-0.16, 0.14]   
Group (PA = 0) 
Sham 0.78 [-0.09, 1.71] 0.12 [-0.30, 0.52] -0.16 [-0.37, 0.05] 0.02 [-0.04, 0.07] -0.05 [-0.13, 0.02] -0.11 [-0.24, 0.03]   
Time x Group (RS2, PA = 0) 
RS1, Sham -0.03 [-1.74, 1.72] 0.34 [-0.32, 1.05] 0.27 [-0.08, 0.64] 0.01 [-0.05, 0.08] 0.03 [-0.07, 0.13] 0.04 [-0.30, 0.34]   
RS3, Sham -0.72 [-2.51, 1.03] 0.65 [0.08, 1.31]* 0.15 [-0.12, 0.44] 0.05 [-0.03, 0.12] 0.05 [-0.05, 0.16] -0.05 [-0.24, 0.15]   






Model term Coefficient estimate [95% CI] 
 Directional hypokinesia (movement initiation time) Directional bradykinesia (movement execution time) 
 Affected hand Unaffected hand Affected hand Unaffected hand 
 Index A Index B Index A Index B Index A Index B Index A Index B 














Time (RS2 = 0) 










































Group (PA = 0) 














Time x Group (RS2, PA = 0) 






















Model term Coefficient estimate [95% CI] 
40.87] 108.58] 45.98] 39.18] 102.07] 211.05] 31.62] 93.84] 
















* Significant effect (95% CI around the coefficient estimate does not include 0). 
The reference condition for dummy variable coding is indicated within parentheses for each term. 







Table 5 Best subsets of factors (as measured in RS1) for predicting overall change in pain intensity 
and CRPS severity throughout the study period (intention-to-treat analysis) 
Best subsets models Adj. R
2
 AIC CV 
Change in pain intensity
†
    
Model 1: (+) Absolute change in handedness* 0.09 -132.24 0.28 
Model 2: (+) Absolute change in handedness*, (+) Index A of directional bradykinesia for 
unaffected hand 
0.13 -119.08 0.29 
Model 3: (+) Oedema difference**, (-) Index B of directional hypokinesia for affected 
hand**, (-) Delta finger-to-palm distance ratio* 
0.25 -105.79 0.30 
Model 4: (+) Oedema difference**, (-) Index B of directional hypokinesia for affected 
hand*, (-) Delta finger-to-palm distance ratio*, (+) Mood disturbance 
0.27 -105.68 0.30 
Model 5: (+) Oedema difference**, (-) Index B of directional hypokinesia for affected 
hand**, (+) Mental Number Line Bisection score*, (+) Absolute change in 
handedness, (-) Delta finger-to-palm distance ratio 
0.32 -107.60 0.35 
Change in CRPS severity
†
    
Model 1: (+) Current pain intensity** 0.13 -50.21 0.58 
Model 2: (+) Current pain intensity**, (-) Index B of directional bradykinesia for 
unaffected hand* 
0.23 -48.39 0.60 
Model 3: (+) Current pain intensity***, (+) Oedema difference*, (+) Hand laterality 
recognition accuracy index* 
0.25 -55.52 0.54 
Model 4: (+) Allodynia on affected limb*, (-) Index B of directional bradykinesia for 
unaffected hand*, (-) Index B of directional hypokinesia for unaffected limb*, 
(+) disease duration 
0.21 -45.66 0.62 
Model 5: (-) Index B of directional bradykinesia for unaffected hand*, (-) Index B of 
directional hypokinesia for unaffected limb, (+) Allodynia on affected limb, (+) 
Disease duration, (+) Body perception disturbance score 








 Predicted outcomes were quantified as individual regression slopes based on pain intensity ratings 
throughout RS1-RS4 and LTFU1-LTFU2, and CRPS severity scores throughout RS1-RS4 (negative slopes indicate 
reductions in pain/CRPS severity). 
* p < .05, ** p < .01, *** p < .001 indicate significant predictors; (+), positive predictor; (-), negative predictor. 
Adj. R
2
, adjusted R-squared; AIC, Akaike Information Criterion; CV, cross-validation error. 






Week 1 Week 5 Week 7 Week 11 Week 19 Week 31
RS1 RS2 RS3 RS4 LTFU1 LTFU2
Daily logbook (10 weeks)
Treatment (2 weeks)
Randomization
Research sessions 1-4: self-report, 
clinical, and neuropsychological 
measures (in person)
Logbook: daily pain, interference, 
and range of movement ratings
Prism adaptation treatment 
(home based)
Sham treatment (home based)







319 invited to take part
143 assessed for eligibility
173 excluded (no response)
80 excluded
• 23 primarily lower limb CRPS
• 19 multiple limbs affected 
• 7 CRPS type II 
• 7 neurological history 
• 6 CRPS diagnostic criteria not met
• 11 declined




• 1 not eligible (multiple limbs 
affected)
• 1 not eligible (no pain)
54 completed RS1
2 excluded
• 1 lost contact
• 1 withdrew (CRPS flare-up)
3 excluded
• 1 lost contact
• 1 withdrew (no time)
• 1 not eligible (pain <2 at RS2)
52 randomised













• 23 Pain intensity 
• 23 CRPS severity
Per-protocol analysis
• 19 Pain intensity
• 21 CRPS severity
Intention-to-treat analysis
• 26 Pain intensity
• 26 CRPS severity
Per-protocol analysis
• 18 Pain intensity
• 20 CRPS severity
2 excluded
• 1 withdrew (unrelated 
illness)
• 1 lost contact
6 excluded
• 1 discontinued (CRPS 
symptoms exacerbation)
• 1 withdrawn by researchers 
(unrelated illness)
• 1 withdrew (CRPS flare-up)
• 2 withdrew (unrelated 
illness)
• 1 withdrew (no time)
• 2 lost contact
• 2 lost contact
26 allocated to Prism 
Adaptation treatment
26 allocated to Sham 
treatment
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